The use of different evidence-based medications and 5-year survival after an acute coronary syndrome: An observational study

Wong, Cheuk‐Kit; Tang, Eng Wei; Herbison, Peter

doi:10.1016/j.ijcard.2007.11.005

Cited by 4 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By assessing the quality among the selected studies related to question number 13, missing data/ loss to follow-up was higher than 20% in the three studies [28], [33], [34]. Referring to question number 18, six studies [8], [15], [21], [35], [36], [37] did not report their study limitation in the discussion part. Thirteen out of 41 studies declared their conflict of interest according to question number 19 in the checklist [9], [10], [16], [18], [19], [24], [26], [28], [33], [34], [38], [39], [40].…”

Section: Study Qualitymentioning

confidence: 99%

“…Thirteen out of 41 studies declared their conflict of interest according to question number 19 in the checklist [9], [10], [16], [18], [19], [24], [26], [28], [33], [34], [38], [39], [40]. Twelve studies did not receive the ethic committee approval nor the participant consent [6], [8], [14], [19], [21], [24], [25], [26], [33], [37], [38], [41]. The details of the assessment are presented in Table 1.…”

Section: Study Qualitymentioning

confidence: 99%

“…This systematic review described the pattern of statin utilization in the ten studies [9], [16], [20], [27], [30], [33], [35], [37], [41], [50], which was prescribed with another ACS medication such as antiplatelet, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and beta-blocker as summarized by Table 3. Seven studies [9], [20], [33], [35], [37], [50] reported the use of statin together with aspirin, beta-blockers, and ACEI/ARB, which was considered as the evidence-based treatment of secondary prevention among the ACS patients. The utility rate of such evidence-based treatment varied from 25% [37] to 86.7% [50].…”

Section: Statin Prescribing Patternmentioning

confidence: 99%

“…Seven studies [9], [20], [33], [35], [37], [50] reported the use of statin together with aspirin, beta-blockers, and ACEI/ARB, which was considered as the evidence-based treatment of secondary prevention among the ACS patients. The utility rate of such evidence-based treatment varied from 25% [37] to 86.7% [50]. The use of statin along with beta-blocker and antiplatelet was reported in five studies [20], [30], [35], [37], [50], with the ranges between 10.1% [20] and 93.2% [30] at discharge.…”

Section: Statin Prescribing Patternmentioning

confidence: 99%

See 3 more Smart Citations

Statin Utilization among Patients with Acute Coronary Syndrome: Systematic Review

Dewi¹,

Thavorncharoensap²

2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: The early use of statin with intensive regimen has been recommended by the recent guidelines as the prevention of acute coronary syndrome (ACS) related events among the high-risk patients. Meanwhile, the inconsistent statin utilization for targeted patient in current practice is still an issue. AIM: This study aims to review the utilization rate of statin among patients with ACS. METHODS: A systematic search of relevant studies published between inceptions to June 2020 was conducted in PubMed. Patients and intervention domains were used to build up the searching formula. A study was eligible for inclusion if it was an original study of patients with ACS and it examined the utilization of statin. The risk of bias was assessed using Axis and NOS checklist. RESULTS: Among the 49 eligible studies, 38 were cohort studies while the others were cross-sectional studies. The utilization rate of statin at hospital admission ranged from 16% to 61% while 25% to 75% during the hospitalization. Of the total studies, 35 studies reported the statin rate at discharge ranging from 58% to 99%. Almost all studies revealed the reduction of statin utilization rate along the follow-up period. The number of statins prescribed was found to be lower among female and elderly patients. CONCLUSION: Despite the established benefits of statin among patients with ACS, our study revealed that statin was underutilized for secondary prevention after ACS. To improve patients’ clinical outcomes with ACS, efforts should be made to increase optimal treatment and compliance with a statin.

show abstract

Section: Study Qualitymentioning

confidence: 99%

Section: Study Qualitymentioning

confidence: 99%

Section: Statin Prescribing Patternmentioning

confidence: 99%

Section: Statin Prescribing Patternmentioning

confidence: 99%

See 2 more Smart Citations

Statin Utilization among Patients with Acute Coronary Syndrome: Systematic Review

Dewi¹,

Thavorncharoensap²

2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…The first admission with ACS was used for analysis if readmissions with ACS were present. Clinical data collected included, among others, [1,2,8,9] baseline characteristics (age, sex, cardiac risk factors, history of ischaemic heart disease, etc. ); presenting clinical features (heart rate, blood pressure, Killip class, episodes of cardiac arrest on arrival and cardiogenic shock); ECG characteristics (degree of STdeviation and T-waves changes); biochemistry (initial and maximum troponin rise, initial creatinine level); left ventricular function on echocardiography; and treatment.…”

Section: Introductionmentioning

confidence: 99%